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Summary This open, multicenter, comparative, randomized study 
included 120 subjects with papulopustular stage of acne vulgaris. Subjects 
were randomized to one of the three treatment groups (A, total dose 4.5 
g of azithromycin in 7 weeks; B, total dose 6.0 g in 10 weeks; and C, total 
dose 7.5 g in 13 weeks). The aim was to identify the optimum azithromycin 
dose in the treatment of acne vulgaris through monitoring the efficacy and 
safety of three dosage regimens. Clinical efficacy was assessed upon 
completion of study therapy and six months of therapy initiation. Post-
therapeutic efficacy assessment was available in 104 subjects. The 
difference between three treatment groups was most pronounced in the 
“cure” category (36.11% in group A, 58.82% in group B and 55.88% in 
group C) and “failure” category (8.33% in group A, and no failures in groups 
B and C).  Follow up efficacy assessment was available in 87 subjects. The 
group percentage of “cure” was lower and group percentage of “treatment 
failure” higher in group A than in groups B and C. Azithromycin in a total 
dose of 6.0 g in 10 weeks seems to be a promising agent in the treatment 
of papulopustular acne vulgaris with few side effects and good patient 
compliance.
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IntroduCtIon
Acne vulgaris is one of the most common 
skin diseases. It affects 80% to 85% of teenag-
ers and young adults (1). In mature adults, up to 
7% may have acne persistently into the mid-30s 
or -40s (2). Lasting for years, acne can cause both 
physical and psychological scarring (3). Acne is a 
multifactorial disease affecting the pilosebaceous 
units of the face and trunk. The pathogenesis of 
acne involves increased sebum production that 
depends on hormonal function, abnormal follicular 
epithelial differentiation causing comedones, and 
proliferation of anaerobic diphtheroid Propionibac-
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terium acnes resulting in inflammation (4). Acne 
is characterized by a variety of non-inflamed and 
inflamed lesions including open and closed com-
edones, papules, nodules and pseudocysts (5). 
In case of moderate inflammatory acne, oral an-
tibiotics are a standard choice of treatment. The 
mechanism of action of systemic antibiotics for 
acne is not entirely clear as it is not only antimi-
crobial; they also diminish chemotaxis of polymor-
phonuclear leukocytes, modify the complement 
pathways and inhibit the polymorphonuclear leu-
kocyte chemotactic factor and lipase production in 
Propionibacterium acnes (6). The most commonly 
prescribed antibiotics for acne are still tetracy-
clines. In order to achieve optimal results these 
antibiotics have to be taken twice or three times 
daily for several months. Such a prolonged anti-
biotic use is often associated with adverse events 
and non-compliance. Besides this, in the past two 
decades there have been an increased number of 
literature reports of Propionibacterium acnes	anti-
biotic resistance to tetracyclines and erythromycin 
(7,8). The increased resistance and poor patient 
compliance with prolonged treatment regimen im-
posed the need of a new antibiotic with a shorter 
duration of treatment.
As azithromycin is an azalide antibiotic struc-
turally related to erythromycin and shows an ex-
cellent	 in vitro	 activity	 against	Propionibacterium 
acnes (9), it was indicated to try its potential in the 
treatment of acne vulgaris.  The efficacy and tol-
erability of azithromycin were tested in the treat-
ment of acne in several clinical studies conducted 
in a limited number of subjects previously treated 
with other antibiotics without success or in whom 
low tolerance was recorded for other antibiotics 	
(10-13).
The aim of this study was to identify the opti-
mum azithromycin dose in the treatment of acne 




The study was designed as an open, multi-
center, comparative, randomized study, and was 
performed at four sites. A total of 120 subjects 
(male or female aged 16 years or older) with 
papulopustular acne vulgaris were enrolled. An 
informed consent was signed by study subjects 
or their parents (legal representatives). The main 
exclusion criteria were macrolide hypersensitiv-
ity, pregnancy, lactation, severe renal or hepatic 
impairment, use of oral contraceptives, glucocor-
ticoids, androgens, antiandrogens, high doses 
of vitamin D and oral isotretionin in the last three 
months.
The study was conducted in accordance with 
the	 Good	 Clinical	 Practice	 guidelines	 and	 prin-
ciples of the Declaration of Helsinki as modified 
at 52nd WMA General Assembly, Edinburgh, Scot-
land, October 2000. 
treatment
Each subject was randomly allocated (Micro-
soft Excel 5.0, RAND() function) at 1:1:1 ratio to 
one of the three treatment groups (group A, total 
dose 4.5 g of azithromycin in 7 weeks; group B, 
total dose 6.0 g in 10 weeks; and group C, total 
dose 7.5 g in 13 weeks).
Study treatment was initiated with a 3-day 
course of 500 mg azithromycin tablet once daily 
followed by one 500 mg azithromycin tablet per	
week for another 6 weeks in group A, 9 weeks 
in group B, and 12 weeks in group C. During the 
study, the subjects were only allowed to apply a 
keratolytic lotion topically twice daily (Rp. Resorci-
num 0.5; Acidum salicylicum 1.5; Aethanolum dilu-
tum 40% ad 100.0). The use of any additional anti-
microbial therapy concomitantly with azithromycin 
was prohibited. In the period following completion 
of study therapy subjects were not allowed to take 
any macrolides, tetracyclines or clindamycin. The 
use of isotretinoin, oral contraceptives, androgens 
or antiandrogens, glucocorticoids, adrenocortico-
tropic hormone, iodide, bromide, isoniazid, topira-
mate, and high vitamin D doses was also prohib-
ited.
Clinical assessment
Clinical examination with recording the number 
of inflamed facial acne lesions was performed be-
fore treatment initiation and subsequently at each 
study visit. Efficacy was assessed at the first visit 
following completion of study therapy (post-thera-
peutic assessment), at 7 weeks of therapy initia-
tion in group A, at 10 weeks of therapy initiation in 
group B, at 13 weeks of therapy initiation in group 
C, and at final visit 6 months of therapy initiation in 
all study subjects (follow up assessment).
Clinical efficacy of the treatment was assessed 
using one of the following categories: “cured”, ef-
florescence count reduced by >75% in relation 
to the pre-treatment status; “improvement”, efflo-
rescence	 count	 reduced	 by	 >50%-74%; “moder-
ate improvement”, efflorescence count reduced 
by	>25%-49%; and “failure”, efflorescence count 
reduced by less than 25%, or deterioration of 
symptoms during azithromycin treatment, or no 
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improvement, or deterioration in acne symptoms 
at 6 months of therapy initiation requiring another 
therapy.
Safety assessment
Adverse events were recorded in all subjects 
during the study. Along with description of the ad-
verse event, the date of onset, duration, severity 
and possible relationship to study treatment were 
recorded.	
Statistics
Statistical analysis was performed using the 
SAS® Stat software (SAS® System, Version 8.00, 
License No. 0082582002). Data were statistically 
analyzed using Fisher exact test and Kruskal-Wal-
lis test. A probability value of p<0.05 indicated a 
statistically significant difference.
reSultS
The study included 120 subjects, 38 male and 
82 female, aged 16-37. There were no statistically 
significant differences among treatment groups 
according to age, body height, body weight, or 
pre-treatment number of facial lesions. Of 120 
subjects enrolled, 93 completed the study, i.e. 
30 in group A, 31 in group B and 32 in group C. 
Post-therapeutic efficacy assessment was avail-
able in 104 subjects. The distribution of clinical 
outcomes in the 3 treatment groups is shown in 
Figure 1. There was no statistically significant be-
tween group difference (Fisher exact test, p=0.28) 
in clinical outcome.
Although not statistically significant, the dif-
ference among the 3 treatment groups was most 
pronounced in the “cure” category: group A, 13/36 
(36.11%); group B, 20/34 (58.82%); and group C, 
19/34 (55.88%), whereas “failure” category was 
exclusively recorded in group A, 3/36 (8.33%).
The difference between the pretherapeutic 
count of facial lesions and post-therapeutic effi-
cacy assessment was significantly lower (Kruskal-
Wallis test, p=0.02) in the low dose (group A) than 
in the mid-dose (group B) and high dose (group C) 
groups (Table 1). The sum of facial lesions at first 
efficacy (post-therapeutic) assessment was also 
significantly higher (Kruskal-Wallis test, p=0.03) in 
the low dose group A as compared with the mid-
dose and high dose groups B and C, respectively 
(Table 2).
Follow up efficacy assessment was available 
in 87 subjects. The distribution of definitive clinical 
outcomes in each treatment group is shown in Fig-
ure 2. At follow up, there were no statistically sig-
nificant differences (Fisher exact test, p=0.07) in 
the distribution of clinical outcomes. Although not 
statistically significant, the percentage of “cure” 
was lower in group A (14/30 (46.67%) as com-
pared with groups B and C (18/28 (64.29%) and 
19/29 (65.82%), respectively). The group percent-
age of “treatment failure” was higher in group A 
(2/30 (6.67%)) than that in group B (1/28 (3.57%)) 
and group C (1/29 (3.45%)).
table 1. Percentage of difference in number of facial lesions before treatment and at post-therapeutic 
efficacy assessment (descriptive statistics included mean and range)








Difference in number of 
facial lesions (%) 61 9	-100 73 34 - 100 74 29 - 100
Figure 1. Distribution of post-therapeutic clinical 
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subject sustained ankle fracture and dropped out 
from follow up. All these seven subjects withdrew 
from the study and had full recovery.
dISCuSSIon
Antibiotics have been used to treat acne for 
over 40 years and are still widely prescribed. 
They remain a common therapeutic option be-
cause of their effectiveness and relative safety on 
long-term use. Their mode of action is partly due 
to their inhibitory effects on cutaneous Propioni-
bacterium acnes, the microorganisms implicated 
in the pathogenesis of the disease. Until the late 
1970s, these organisms were uniformly sensitive 
to therapeutically useful antibiotics (14). Since 
then, an association has been found between the 
carriage of resistant strains and failure to respond 
to treatment with the corresponding antibiotic (8). 
The most frequently prescribed antibiotics in-
table 2. Sum of facial lesions at post-therapeutic efficacy assessment (descriptive statistics included 
mean and 95% confidence interval)
Group A (n=36) Group B (n=34) Group C (n=34)
Mean 95% CI Mean 95% CI Mean 95% CI
Sum of facial 
lesions 15.4 12.4 – 18.4 11.4 8.1 – 14.6 9.1 7.4 – 10.7
Figure 2. Distribution of follow up clinical efficacy 



















































Safety assessment was performed in all sub-
jects that received at least one dose of azithro-
mycin. A total of 27 adverse events in 21 subjects 
were recorded. The majority of adverse events 
included laboratory findings, i.e. elevation of liver 
enzymes, and gastrointestinal adverse events. All 
of these adverse events were previously known 
and none of the reported adverse events was re-
ported as unexpected. The incidence of adverse 
events according to treatment groups is presented 
in Table 3. There was no statistically significant dif-
ference in the occurrence of adverse events be-
tween the three treatment arms (Fisher exact test, 
p = 0.07). The distribution of adverse events, pos-
sibly and definitely connected and not connected 
to the treatment, is presented in Table 4.
Three subjects had elevated AST above the 
upper normal limit (UNL); only one of them had 
a clinically significant rise (1.5xUNL) in AST; one 
subject had a clinically significant rise (1.5xUNL) 
in ALT. One subject suffered from stomach pain 
and diarrhea; one subject had exacerbation of 
facial flat warts (verucae planae faciei); and one 
Figure 2. Distribution of follow up clinical efficacy 
outcomes in three treatment groups (n=87)
Treatment
No. of subjects 
TotalFrequency
With AEs Without	AEsRow %
Col %
A
n 11 29 40
% 27.50 72.50 100.00
% 52.38 29.90 33.90
B
n 6 33 39
% 15.38 84.62 100.00
% 28.57 34.02 33.05
C
n 4 35 39
% 10.26 89.74 100.00
% 19.05 36.08 33.05
Total
n 21 97 118
% 17.80 82.20 100.00
% 100.00 100.00 100.00
table 3. Distribution of subjects with adverse 
event (AE) incidence in 118 subjects (frequency, 
row and column percent)
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clude tetracyclines (oxytetracycline, minocycline 
and doxycycline) and erythromycin, which need 
to be taken daily for several months, thus often 
entailing low patient compliance, which is another 
parameter relevant for the treatment and its suc-
cess. Due to the relatively low compliance and 
the emergence of tetracycline and erythromycin 
resistant strains of Propionibacterium acnes, the 
need of alternative antibiotic treatment with less 
frequent dosing and shorter therapy duration has 
become evident.
The anti-inflammatory action of macrolides 
has been shown in various studies. They affect 
several inflammatory processes such as migra-
tion of neutrophils, oxidative burst of phagocytes 
and production of proinflammatory cytokines (15-
17). Azithromycin has a superior pharmacoki-
netic profile when compared to other macrolides. 
It penetrates tissue rapidly, where it remains for 
prolonged periods. This enables less frequent 
dosing and shorter therapy duration. Moreover, it 
shows affinity for inflammatory tissues (18). Be-
sides azithromycin effectiveness in the treatment 
of inflammatory acne (19), there also are reports 
of its effectiveness in the treatment of inflamma-
tory rosacea (20).
Because azithromycin shows an excellent in vi-
tro efficacy against Propionibacterium acnes with 
an extended therapeutic effect after the last dose 
and good penetration into the skin (9), several 
investigators have evaluated safety and efficacy 
of this antibiotic in the treatment of acne vulgaris. 
Regardless of differences in dosing regimens and 
comparative treatments, the results of all these 
studies suggested that azithromycin could become 
standard therapy in the management of acne.
The safety and efficacy of azithromycin in the 
treatment of acne vulgaris was evaluated in sub-
jects who had previously been unsuccessfully 
treated with other antibiotics. In this study, sub-
jects received azithromycin for three months; once 
daily for 5 days twice a month up to a total dose 
of 9 g and once daily for 5 days once a month for 
the remaining 2 months. This intermittent dosing 
of azithromycin was found to be very effective and 
also resulted in improved compliance (10).
In a comparative study including 72 subjects 
with moderate to severe acne, azithromycin in a 
total dose of 8 g (4 cycles of 500 mg daily for 4 
days) was found to be somewhat more efficacious 
and as well tolerated as minocycline 100 mg ad-
ministered daily for 6 weeks (at the 6 week as-
sessment clinical improvement was observed in 
76% of subjects treated with azithromycin and in 
71% of those treated with minocycline (12).
In a retrospective study comparing various 
oral antibiotic treatments for acne, azithromycin 
(single oral 250 mg dose of azithromycin 3 times 
weekly for a mean of 11.67 weeks) showed equal 
or better efficacy and tolerability than cefuroxime, 
doxycycline, erythromycin, minocycline and tetra-
cycline (11,21).
A randomized comparative study evaluated the 
role of a monthly dose of azithromycin and com-
pared it to daily doxycycline. Sixty subjects with 
moderate to severe acne were randomly assigned 
to two treatment groups. In the first group subjects 
received 100 mg doxycycline daily in addition to 
topical 0.05% tretinoin cream, whereas subjects in 
the second group were given 500 mg azithromy-
cin once a day for four days per month along with 
0.05% topical tretinoin for a total of 12 weeks. The 
monthly dose of azithromycin was found to be as 
efficacious as daily doxycycline (22).
The open-label, non-comparative study includ-
ing 35 subjects with relapsing moderate to severe 
papulopustular acne showed that treatment with 
azithromycin, 500 mg three times weekly for 12 
weeks, was effective in 82.9% of subjects with a 
nearly 60% reduction of lesions in the first 4 weeks 
and 80% in 12 weeks (13).
table 4. Distribution of adverse events (AE), pos-
sibly and definitely connected and not connected 
to treatment (frequency, row and column percent)











n 12 1 13
% 92.31 7.69 100.00
% 52.17 25.00 48.15
B
n 7 2 9
% 77.78 22.22 100.00
% 30.43 50.00 33.33
C
n 4 1 5
% 80.00 20.00 100.00
% 17.39 25.00 18.52
Total
n 23 4 27
% 85.19 14.81 100.00
% 100.00 100.00 100.00
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In our open, multicenter, randomized study we 
compared three dosage regimens of azithromy-
cin in pulse therapy of acne vulgaris: a cumula-
tive dose of 4.5 g, 6.0 g, and 7.5 g  over 7, 10 
and 13 weeks, respectively. The initial efficacy as-
sessment was performed at the end of therapy in 
each treatment group, and follow up evaluation at 
6 months of inclusion into the study. The results 
indicated that there were differences among treat-
ment groups when comparing the sum of lesions 
or its change over time. With respect to these two 
efficacy measures, treatment with 4.5 g azithro-
mycin was found to be less effective than treat-
ments with 6 g and 7.5 g.
There was no statistically significant difference 
in the occurrence of adverse events (in total or 
with respect to treatment) among the three treat-
ment arms. The majority of adverse events includ-
ing those that were labeled as potentially treat-
ment-related occurred in the low dose group A. 
These findings indicated that the adverse events 
observed could not be linked to treatment duration 
or cumulative dose of azithromycin received.
In conclusion, no significant difference was 
found in the efficacy and safety between the treat-
ment groups receiving 6.0 g and 7.5 g of azithro-
mycin, but it seemed that the advantage of mid-
dose azithromycin (6.0 g) might result in better pa-
tient compliance and definitely in lower cost. So, 
it appears that azithromycin in a total dose of 6.0 
g is a promising agent in the treatment of papulo-
pustular stage of acne vulgaris with its few side 
effects and good patient compliance. These 10 
weeks of pulse therapy represented a rationale for 
launching a pivotal, comparative study to establish 
the potential clinical benefit of azithromycin in the 
treatment of acne vulgaris.
acknowledgment
This study was supported by Pliva Croatia Ltd., 
Zagreb, Croatia.
references
1.   Usatine RP, Quan MA, Strick R. Acne vulgaris: 
a treatment update. Hosp Pract 1998;33:111-
27.
2.   Goulden V, Cunliffe WJ. Post adolescent acne 
– a review of the clinical features. Br J Der-
matol 1997;136:66-70.
3.   Koo J. The psycho social impact of acne: 
patient’s perceptions. J Am Acad Derm 
1995;32:S25-S32.
4.   Cunliffe WJ. Acne. London: Martin Dunitz; 
1989.
5.   Thiboutot DM, Strauss JS. Diseases of the 
sebaceous glands. In: Freedberg IM, Eisen 
AZ, Wolff K, Austen KF, Goldsmith LA, Katz 
SI, editors. Fitzpatrick’s Dermatology in Gene-
ral Medicine. 6th ed. New York: Mc Graw-Hill; 
2003. pp. 672-87.
6.   Meynadier J, Alirezai M. Systemic antibiotics 
for acne. Dermatology 1998;196:135-9.
7.   Eady EA, Jones CE, Tipper JL, Cove JH, Cun-
liffe WJ, Layton AM. Antibiotic resistant propio-
nibacteria in acne: need for policies to modify 
antibiotic usage. Br Med J 1993;306:555-6.
8.   Drenol B, Legallou F, de Sain Marie I. Preva-
lence of erythromycin resistant propionibacte-
ria in acne patients in France. J Invest Der-
matol 1997;108:379.
9.   Peters DH, Friedel HA, McTavish D. Azithro-
mycin. A review of its antimicrobial activity, 
pharmacokinetic properties and clinical effi-
cacy. Drugs 1992;44:750-99.
10. Elewski BE. Pulse azithromycin is effective in 
inflammatory acne vulgaris. Presented as a 
poster at the 4th International Conference on 
the Macrolides, Azalides, and Streptogramins, 
Barcelona, Spain, January 1998.
11. Fernandez-Obregon AC. Azithromycin for the 
treatment of acne. Int J Dermatol 1997;36:	
239-40.
12. Gruber F, Grubišić-Greblo H, Kaštelan M, 
Brajac I, Lenković M, Zamolo G. Azithromycin 
compared with minocycline in the treatment 
of acne comedonica and papulo-pustulosa. J 
Chemother 1998;10:469-73.
13. Kapadia N, Talib A. Acne treated successfully 
with azithromycin. J Dermatol 2004;43:766-7.
14.	Leyden	 JJ.	 Antibiotic	 resistant	 acne.	 Cutis	
1976;17:593-6.
15. Labro MT. Anti-inflammatory activity of macro-
lides: a new therapeutical potential? J Antimi-
crob Chemother 1998;418:37-46.
16. McDonald PJ, Pruul H. Phagocyte uptake and 
transport of azithromycin. Eur J Clin Microbiol 
Infect Dis 1991;10:828-33.
17. Scaglione F, Rossoni G. Comparative anti-in-
flammatory effects of roxithromycine, azithro-
Basta-Juzbašić et al.     Acta Dermatovenerol Croat
Azithromycin in treatment for acne vulgaris      2007;15(3):141-147 
ACTA DERMATOVENEROLOGICA CROATICA
147
mycin and clarithromycin. J Antimicrob Che-
mother 1998;41:47-50.
18. Allvarez-Elcoro S, Enzler MJ. The macrolides: 
erythromycin, clarithromycin, azithromycin. 
Mayo Clin Proc 1999;74:613634.
19. Braun-Falco O, Plewig G, Wolff HH, Burgdorf 
WHC. Acne. In: Braun-Falco O, Plewig G, 
Wolff HH, Burgdorf WHC, editors. Dermato-
logy.	4th ed. Berlin: Springer-Verlag; 1996. pp. 
1053-70.
20. Bakar O, Demircay Z, Gurbuz O. Therapeuti-
cal potential of azithromycin in rosacea. Int J 
Dermatol 2004;43:151-4.
21. Fernandez-Obregon AC. Azithromycin for the 
treatment of acne. Int J Dermatol 2000;39:	
45-50.
22. Parsad D, Pandhi R, Nagpal R, Negi KS. Azith-
romycin monthly pulse vs. daily doxycyline in 
the treatment of acne vulgaris. J Dermatol 
2001;28:1-4.
Basta-Juzbašić et al.     Acta Dermatovenerol Croat
Azithromycin in treatment for acne vulgaris      2007;15(3):141-147 
ACTA DERMATOVENEROLOGICA CROATICA
Before powdering your face use Nivea cream; year 1936.
(from the collection of Mr. Zlatko Puntijar)
	
